NIAID announces contracts to fight bioterrer

The U.S. National Institute of Allergy and Infectious Diseases, part of the National Institutes of Health, recently announced the formulation of three new contracts to fund research on vaccines intended to protect the country in the case of bioterror attack or an emerging infectious disease.

Each project is focused on a simple and efficient means of delivery that could be deployed quickly in the case of an emergency. Depending on the level of completion, the funding for the three contracts could reach $68 million, according to Xinhua.

Emergent BioSolutions, Inc., will develop an anthrax vaccine under the terms of the contract. Their candidate vaccine consists of a licensed vaccine combined with an adjuvant. The other projects will focus on an oral anthrax vaccine and a dengue fever vaccine delivered with a needle free device.

"These new contracts build on NIAID's commitment to support the advanced development of products that are important to the public health but often unattractive to investors in private industry, by bridging the funding gap with contracts intended to address specific health needs," NIAID Director Anthony S. Fauci told Xinhua.

"Our goal is to improve vaccine delivery and the resulting immune response in a way that could be used to protect large numbers of patients," Michael G. Kurilla, director of the Office of Biodefense Research Affairs in NIAID's Division of Microbiology and Infectious Diseases, said, Xinhua reports.

Organizations in this story

National Institutes of Health 9000 Rockville Pike Bethesda, MD 20892

Get notified the next time we write about National Institutes of Health!